Goldman Sachs Initiates Coverage on Tianhang Medical: Domestic Leader but Overseas Validation Remains to Be Seen, Rating Neutral

Overview

Goldman Sachs initiates coverage on Tianhang Medical (688277.SS) with a Neutral rating and a target price of RMB21.8. The report recognizes Tianhang Medical as a leader in Chinese orthopedic surgical robots, maintaining an approximately 40% cumulative tender market share from 2021-2025. However, the firm believes the company's current business model is still unclear in monetizing consumables, and its overseas expansion strategy into developed markets faces intense multinational competition, requiring a 1-2 year commercialization validation period. Therefore, although it is optimistic about long-term growth potential, it maintains a relatively Neutral view until delivery volume, utilization, and repeat orders provide stronger validation.

Core views

Domestic market competition intensifies but the leading position remains solid. Leveraging early installed base and clinical adoption, Tianhang Medical has built a deep domestic moat, with 89 cumulative tender wins from 2021-2025 and a market share of approximately 40%. Although 25 orthopedic surgical robots received NMPA approval in 2025 and product homogenization has intensified competition, management's 2026 targets (win rate ≥40%, new installations >60 units) are largely consistent with the current trajectory. As the installed base expands, the 2026 surgery volume target of approximately 60,000 cases provides visibility into underlying demand. The consumables business is the long-term core driver, but its contribution will increase gradually. Unlike Stryker, which achieves a closed consumables loop through Mako robots, Tianhang's current open-system architecture limits its full internalization of surgical-level economics. Although TiRobot II and third-generation models support more consumables categories, the increase in consumables revenue share depends on the pace of new model installations and the clarification of domestic pricing policies. In 2025, consumables and service revenue accounted for 43%; Goldman Sachs expects this ratio to stabilize around 40% by 2030, rather than management's target of 70%, mainly because rapid growth in overseas system sales will dilute the consumables share. The overseas strategy is shifting toward developed countries, and commercialization still needs validation. From 2025, Tianhang is shifting its overseas focus from emerging markets to developed regions such as the US, Europe, and Australia to capture greater market space and monetization potential. Although registration progress is smooth, commercialization and brand building are expected to require a 1-2 year runway given entrenched multinational competition in these markets. Goldman Sachs takes a cautious view on the ramp-up speed, identifying early adoption rates, utilization, and repeat orders as key validation metrics. Financials and valuation: 2025-2030E sales CAGR is expected to be 30%, but due to continued investment in overseas market development and domestic system price pressure, the net profit break-even point is postponed to 2029 (versus management guidance of 2026/2027). Gross margin is expected to decline slightly to 66% in 2026 due to a higher distributor channel share and the launch of lower-priced models, then recover as the high-margin overseas business share rises. Based on a 10-year DCF model (discount rate 9%, terminal growth rate 3%), the target price is RMB21.8, corresponding to 2026-2028 P/S multiples of 28x, 21x, and 16x.

Analysis framework

Goldman Sachs adopted a typical growth-stage medical device company analytical framework. First, it confirmed the company's domestic market share and competitive position through tender data and installed base (supply-demand framework and industry concentration analysis). Second, it dissected revenue structure in depth, comparing Stryker Mako's "robot + consumables" closed-loop model to evaluate the monetization potential and growth speed of Tianhang's consumables business under an open-system architecture (value chain analysis and substitution effect analysis). Third, on the overseas logic, in addition to registration progress, it emphasized the "validation period" for commercialization and the competitive landscape (competitor analysis within Porter's Five Forces). Finally, on valuation, given the company is not yet profitable, it used a DCF model rather than P/E valuation, and cross-checked against P/S multiples of comparable surgical robot companies.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  DCF Discounted Cash Flow Model

  For growth-stage technology companies that are not yet profitable or are in a high-investment period, traditional P/E valuation becomes ineffective. The DCF model more accurately reflects long-term intrinsic value by forecasting future free cash flows and discounting them to the present. Goldman Sachs used a 9% discount rate and 3% terminal growth rate here.

• Industry/Industrial Analysis FrameworkValue chain analysis

  Robot-Consumables Closed Loop vs. Open System

  In the surgical robot industry, closed systems (e.g., Stryker Mako) can generate substantial and recurring downstream revenue by tying in proprietary consumables; open systems allow third-party consumables, which facilitates early adoption but weakens the manufacturer's control over subsequent high-margin segments. This is the key logic for assessing Tianhang Medical's long-term profitability.

• Competition and Strategy FrameworkPorter's five forces

  Threat of Existing Competitors

  The report notes that 25 orthopedic robots were approved in 2025, with product convergence intensifying domestic competition; at the same time, it faces entrenched competition from multinational giants in developed overseas markets. This high-intensity competitive environment directly affects the company's pricing power and market expansion speed.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 天航医疗 (688277.SS)

  Subject company; domestic leader in orthopedic surgical robots

  Strengths

  Domestic cumulative tender share of approximately 40%, large installed base, increasing clinical penetration

  Weaknesses

  Open-system architecture limits consumables monetization, overseas commercialization faces fierce competition, profit timeline delayed

  Comparison

  Compared with Stryker's closed-loop ecosystem, Tianhang has weaker consumables synergy effects; compared with other domestic emerging competitors, it has first-mover advantage and brand recognition

  Risks

  R&D and commercialization progress below expectations, intensified competition, uncertainty in medical service pricing policies

Key data

• Target PriceRMB21.8Based on a 10-year DCF model, implying 9% upside
• Domestic Cumulative Tender Share约40%2021-2025 data, reflecting domestic leadership
• 2025-2030E Sales CAGR30%Driven by new model sales, consumables volume growth, and overseas expansion
• Net Profit Break-even Year2029ELater than management guidance of 2026/2027 due to overseas investment and price pressure
• 2025 Consumables and Service Revenue Share43%Expected to remain around 40% by 2030, below management's 70% target
• 2026E Gross Margin66%Slight decline from 69% in 2025 due to higher distributor channel share

Impact & implications

For investors, Tianhang Medical's core investment thesis lies in the stability of its domestic leadership position and the growth optionality from future consumables and overseas businesses. However, the report cautions that the current share price already reflects some expectations and lacks near-term catalysts. If the company can demonstrate strong overseas order execution or accelerated consumables penetration in the coming quarters, the rating could turn positive. Conversely, if commercialization progresses slower than expected, there is a risk of valuation correction.

Risks

• R&D and commercialization progress in domestic and overseas markets slower or faster than expected, affecting revenue recognition
• Deterioration in the competitive environment, especially domestic product homogenization and direct competition from overseas multinational giants
• Uncertainty in surgical and service pricing policies; stronger hospital bargaining power may suppress short-term profitability

What to watch

• Overseas order conversion in the coming quarters
• Installation speed of TiRobot II and third-generation models and changes in consumables penetration
• Specific implementation details of provincial medical service price catalogs and their actual pull effect on installed volume